Sign in to view content

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD

Peter A. Campochiaro, MD

Video
Published 2020

Related

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2024
Gene Expression Modifications in Anti-VEGF Treated Retinal Müller Cells
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2016

Category: AMD-Neovascular

See more